Aureka Biotechnologies is a tech-bio company founded in 2023 with R&D operations in Suzhou and California that develops antibody therapeutics through its proprietary AuraIDE generative-AI platform. The platform pairs foundation models and AI agents with a high-throughput single-cell functional screening system to design differentiated antibodies for cardiometabolic, immune, and central-nervous-system disease targets that are difficult to address with conventional discovery methods. The company has built a BD/NewCo collaboration model with multiple multinational pharmaceutical companies and is preparing its first internally-designed antibody to enter clinical trials.
1
Round
5
Tags
Apr 27, 2026
Latest raise
Funding activity · 1 round
Apr 27, 2026
$35M
Series A
Led by HongShan (ex Sequoia China)
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
